Phase I of Brilife Trial Comes to a Close
Trial of the COVID-19 vaccine developed by the Israel Institute of Biological Research is set to move into Phase II within a few weeks.
A Step Closer to Finding a Cure for Cancer with CRISPR-Cas9
Recent research conducted in Israel showed how the CRISPR-Cas9 gene editing system can be effective against metastatic cancer.
New Collaboration Between Sheba and Toronto General
A recent partnership between Sheba and Toronto General aims to advance lung transplantation in Israel, revolutionizing how the procedure is performed.
In the Family: First Recipient of COVID-19 Vaccine at Sheba is Grandson of Virology Lab Director
Two more reasons to be proud of our Sheba family! Prof. Ella Mendelssohn, director at Sheba’s Virology Lab, was the first scientist to receive a sample of the coronavirus in Israel.
“Soapy” Saves Lives – Israeli-Invented Sink for Better Hand Hygiene
Proper hand hygiene is a vital part of preventing the spread of COVID-19, and an Israeli company has redesigned the sink to help people get squeaky clean.
Sheba Reports Increasing Number of Patients with Chronic COVID
Hospitals in Israel report a high number of patients suffering from chronic COVID. In this condition, various serious symptoms appear after recovery, and they can last a long time.
Ministry of Health 2019 Report Recognizes Sheba for Excellence in Health Care
For the second year in a row, the Ministry of Health’s National Quality Indicators Report recognized Sheba as a leading force in health care quality and patient safety.
Back to School During COVID-19 – Sheba Implements Creative Solution
To keep schools open for safe learning, an inventive pilot program for rapid corona testing was designed by Sheba and launched this week.
Man’s Life is Saved by High-Tech Device from Israeli Startup
Thanks to a groundbreaking flexible microcatheter developed by BENDIT Technologies, a 74-year old man suffering from a “giant” brain aneurysm survived.
First Volunteer Receives BriLife Corona Vaccine
Depending on the response to the vaccine, the trial is expected to expand to about 80 volunteers and last approximately one month.
